[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100358840":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":45,"responsibleParty":65,"collaborators":43,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":43,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":43,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":48,"whyStopped":43,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral administration","ACTIVE_COMPARATOR","Oral oxybutynin (5mg) is administered in the preoperative area prior to surgery. The current regimen is to mix the oxybutynin with the standard preoperative Versed so children do not have to take two dosages.\n\nPost-operatively oral oxybutynin (5mg) is administered every 8 hours in the hospital.",[13],"Drug: Oral Oxybutynin",{"label":15,"type":16,"description":17,"interventionNames":18},"Transdermal administration","EXPERIMENTAL","Guardian will be given the transdermal patch (3.9mg oxybutynin) at the preoperative appointment with instructions to apply the day prior to surgery. While in the hospital no oral oxybutynin will be prescribed.",[19],"Drug: Oxybutynin Transdermal Patch",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Oxybutynin Transdermal Patch","Transdermal patch of oxybutynin will be used instead of oral oxybutynin.",[15],[27],"Ditropan XL",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Oral Oxybutynin","Oral administration of oxybutynin (5mg) every 8 hours in the hospital.",[9],[27],[34],{"name":35,"affiliation":36,"role":37},"Eric A Kurzrock, MD","UC Davis Health Center","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Anjali Vij, BS","CONTACT","9167345173",null,"avij@ucdavis.edu",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of California Davis Medical Center (UCDMC)","RECRUITING","Sacramento","California","95817","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-121.4944,38.58157,{"lat":58,"lon":57},[61,64],{"name":35,"role":41,"phone":62,"phoneExt":43,"email":63},"916-734-6490","eakurzrock@ucdavis.edu",{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},{"type":66,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100358840","phase-3-oxybutynin-for-post-surgical-bladder-pain-and-urgency-100358840",false,"NCT03952299","Oxybutynin for Post-surgical Bladder Pain and Urgency","Inclusion Criteria:\n\n* Patients who will undergo bladder surgery that requires an indwelling bladder catheter after surgery.\n* Age Range: Four to 8 years of age are eligible for the study.\n\nExclusion Criteria:\n\n* Patients who have had prior bladder surgery.\n* Patients who have neurologic disease that could impair bladder sensation.\n* Patients who are already taking antimuscarinic or antispasmodic medications.\n* Patients with glaucoma, any neurologic disease, dementia, impaired mentation or disorder of the central nervous system.\n* Patients taking any medication that affects the central nervous system such as antidepressant, anxiolytic or antipsychotic medications.\n* Less than four years of age cannot have the transdermal patch due to fixed dose. Over 8 years of age: less than 5% of our patients, who undergo this surgery, are over 8 years of age and is usually a rare adolescent. Data in an older cohort may confuse the results since they respond differently to bladder surgery due to larger incision and longer hospital stay with a catheter.","ALL","4 Years","8 Years",{"count":77,"type":78},100,"ESTIMATED","INTERVENTIONAL",[81],"PHASE3","Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.",[84,85],"Overactive Bladder Syndrome","Neuropathic Bladder",[87],"Transdermal Oxybutynin","2026-01-28",{"date":90,"type":91},"2026-01-29","ACTUAL",{"date":93,"type":91},"2021-09-01",{"date":95,"type":78},"2026-12-31",{"name":5,"class":6},1]